Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada

法雷奥制药公司获得加拿大700家医院和医疗保健机构的Redesca上市

2021-10-13 21:00:03 BioSpace

本文共1206个字,阅读需4分钟

2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario MONTREAL, Oct. 13, 2021 /PRNewswire/ - Valeo Pharma (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has been awarded two multi-year listing agreements  by two of Canada's largest Group Purchasing Organizations ("GPO") for Redesca as well as  three additional hospital specialty products. Under the terms of the contracts, the GPOs have listed Redesca™ and Redesca HP™, Valeo's leading low molecular weight heparin ("LMWH") biosimilar, as well as three other hospital products (Amikacin, Ethacrynate Sodium and Benztropine), for a 3-year period starting on October 1, 2021. "These listing agreements significantly expand the number of Canadian hospitals that can now access Redesca. Increased hospital accessability, coupled with extensive public and private reimbursement coverage, provides a solid foundation to support the continued growth of Redesca. The Canadian hospital market is highly sought-after and competitive, our commercial team continues to delivery results in this environment ", said Steve Saviuk, Chief Executive Officer. Commenting on the GPO contract signature, Frederic Fasano, President and Chief Operating Officer said, "Our new corporate structure and commercial platform allow us to successfully pursue and develop strong partnerships with leading GPO across the country and better service their evolving needs. The support provided by our dedicated team of key account managers and medical affairs professionals combined with the strong supply chain in place make Redesca's value proposition very attractive for hospitals".   About Valeo Pharma Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter. Forward Looking Statements This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. multimedia:https://www.prnewswire.com/news-releases/valeo-pharma-obtains-listings-for-redesca-in-700-hospitals-and-healthcare-facilities-across-canada-301398850.html
2个集团采购组织的上市协议涵盖,Redesca™和Redesca惠普™,以及其他3个法雷奥医院产品 2个多年期产品于2021年10月1日开始上市 GPO代表了包括安大略省在内的5个省的700多家医院和医疗保健机构 蒙特利尔2021年10月13日电/PRNewswire/--加拿大制药公司法雷奥制药(CSE:VPH)(OTCQB:VPHIF)(FSE:VP2)(“法雷奥”或“公司”)今天宣布,它已获得加拿大两个最大的集团采购组织(“GPO”)授予的两项多年上市协议,用于Redesca以及另外三项医院特色产品。 根据合同条款,GPO已将雷德斯卡™公司和雷德斯卡惠普™公司、法雷奥领先的低分子肝素(“LMWH”)生物类似物以及其他三种医院产品(阿米卡星、乙炔酸钠和苯甲托品)上市,从2021年10月1日起为期3年。 “这些上市协议大大增加了现在可以进入REDESCA的加拿大医院的数量。医院可用性的提高,加上广泛的公共和私人报销覆盖面,为支持REDESCA的持续增长提供了坚实的基础。加拿大医院市场非常抢手,竞争激烈,我们的商业团队继续在这种环境下交付成果,”首席执行官史蒂夫·萨维克说。 总裁兼首席运营官Frederic Fasano在评论GPO合同签署时表示:“我们新的公司结构和商业平台使我们能够成功地追求和发展与全国领先的GPO的强大合作伙伴关系,并更好地服务于他们不断变化的需求。我们专注的大客户经理和医疗事务专业人员团队提供的支持,加上强大的供应链,使REDESCA的价值主张对医院非常有吸引力”。 关于法雷奥制药 法雷奥制药是一家加拿大制药公司,致力于创新处方产品在加拿大的商业化,专注于呼吸道疾病病、神经退行性疾病、肿瘤学和医院特色产品。法雷奥制药公司总部位于魁北克省柯克兰,拥有所有必要的能力和完整的基础设施,以注册和适当管理其不断增长的产品组合,通过商业化的所有阶段。欲了解更多信息,请访问www.valeopharma.com,并在LinkedIn和Twitter上关注我们。 前瞻性陈述 本新闻稿包含关于法雷奥目标、战略和业务的前瞻性陈述,涉及风险和不确定性。这些陈述是“前瞻性”的,因为它们是基于我们目前对我们经营的市场的预期以及各种估计和假设。如果已知或未知的风险影响我们的业务,或者如果我们的估计或假设被证明是不准确的,实际事件或结果可能与这些前瞻性陈述中的预期有重大差异。 加拿大证券交易所及其法规服务提供商都没有审查或承担责任的充分性或准确性本新闻稿。 多媒体:https://www.prnewswire.com/news-releases/valeo-pharma-gaets-listings-for-redesca-in-700-hospitals-and-healthcare-facilities-across-canada-301398850.html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文